Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02623972 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
A Phase 2 study of Inflammatory Breast Cancer and Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 2
- Study locations
NCT02623972 is a Phase 2 study of Inflammatory Breast Cancer and Human Epidermal Growth Factor 2 Negative Carcinoma of Breast that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 22 participants, below the 90-participant average among 5 other Inflammatory Breast Cancer trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02623972, a Phase 2 study of Inflammatory Breast Cancer and Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying a drug called eribulin combined with standard treatment as a possible preoperative treatment for HER2 negative inflammatory breast cancer.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Eribulin
- DRUG Adriamycin
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-02-26 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02623972
The ClinicalTrials.gov registry entry for NCT02623972 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 5 other Inflammatory Breast Cancer trials with a reported enrollment target (76% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Inflammatory Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT02623972 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02623972 about?
NCT02623972 is a clinical study titled "A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer". This research study is studying a drug called eribulin combined with standard treatment as a possible preoperative treatment for HER2 negative inflammatory breast cancer.
What is the current status of trial NCT02623972?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2016-02-26. Estimated completion is 2026-12.
What conditions does trial NCT02623972 study?
This clinical trial studies the following conditions: Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast.
What interventions are being tested in trial NCT02623972?
The interventions under investigation include: Cyclophosphamide (DRUG), Eribulin (DRUG), Adriamycin (DRUG).
Who is sponsoring clinical trial NCT02623972?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02623972 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammatory Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
COMPLETED · Phase 2
-
Refining Local-Regional Therapy for IBC
RECRUITING · NA
-
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
RECRUITING · NA
-
Onvansertib + Paclitaxel In TNBC
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Inflammatory Breast Cancer
All registered trials for this condition
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.